Table 1

Comparison of baseline variables across trajectories of longitudinal fatigue

	No fatigue	Improved fatigue	Continued fatigue	No fatigue vs improved fatigue	No fatigue vs continued fatigue	Improved fatigue vs continued fatigue
Number	61	33	53	p	p	p
Age (years)	52.92 (12.46)	51.70 (11.46)	53.15 (13.59)	0.64	0.92	0.61
Female gender	44 (72.13)	27 (81.82)	47 (88.68)	0.29	0.03	0.37
Higher Education	39 (63.93)	23 (67.70)	22 (44.00)	0.30	0.04	0.02
Anti-CCP positive	44 (72.13)	26 (81.25)	50 (96.15)	0.33	0.001	0.02
RF positive	32 (55.17)	21 (72.41)	38 (80.85)	0.12	0.002	0.39
Disease duration	8.12 (6.97)	7.16 (7.34)	11.71 (10.02)	0.54	0.10	0.03
RA disease activity
Swollen joints (28)	5.62 (5.07)	6.45 (5.84)	6.70 (5.00)	0.47	0.26	0.84
CRP (mg/L)	9.92 (15.62)	16.85 (21.93)	12.02 (20.28)	0.16	0.86	0.12
Calprotectin (mg/L)	1.73 (1.69)	2.11 (2.04)	1.47 (1.19)	0.80	0.38	0.46
Sum PD	14.74 (12.99)	15.64 (16.10)	12.51 (11.65)	0.77	0.34	0.30
Sum GS	31.45 (18.49)	30.82 (21.12)	28.49 (16.44)	0.88	0.37	0.57
PROMs
Patient global VAS	27.15 (21.90)	45.61 (25.66)	68.36 (19.47)	<0.001	<0.001	<0.001
Tender joints (28)	2.84 (3.46)	3.82 (3.41)	9.79 (7.91)	<0.19	<0.001	<0.001
RAID sleep	1.28(1.63)	4.61 (2.62)	6.15(2.51)	<0.001	<0.001	0.01
RAID fatigue	1.61 (1.14)	5.70(1.36)	7.11 (1.86)	<0.001	<0.001	<0.001
Widespread pain	4.34 (2.90)	6.73 (4.12)	8.26 (5.30)	0.002	<0.001	0.16
HADS anxiety	1.28 (2.05)	1.33 (3.14)	4.06 (5.42)	0.92	<0.001	0.01
HADS depression	0.72 (1.55)	0.90 (2.14)	3.66 (4.89)	0.57	0.004	0.003
Pain Catastrophizing	1.18 (1.02)	2.57(1.44)	2.89 (1.42)	<0.001	<0.001	0.20

Bivariate analyses No fatigue: Fatigue ≤3 at baseline and at 4/5 visits. Improved fatigue: Fatigue ≥4 at baseline, but ≤3 at 6- and 12-months visit. Continued: Fatigue ≥4 at 5/6 visits.
GS, Grey scale; HADS, Hospital anxiety and depression scale; PD, Power D oppler; VAS, Visual analogue scale. Disease duration in years.